|
Westwood,
Massachusetts,
December 7, 2009.
CompuCyte Corporation, the pioneer in the field of
imaging cytometry instrumentation and the leading supplier of
laser scanning cytometers, announced that it has expanded its
state-of-the art iGeneration line of imaging cytometers to
include four-laser versions of the iCyte®, iCys® and iColor®
systems. With the option of four excitation lasers chosen from a
palette of 405, 488,
532, 561, 594 and 633 nanometers, these newly released
analyzers dramatically increase system flexibility when using
multiple fluorescent and chromatic dyes and take the definition
of high-content cellular and tissue analysis to a new level.
Mel Henriksen,
CompuCyte’s Vice President of Research and Development,
explained the significance of the company’s technological
advance. “The
recent development of fluorescent proteins that emit light in
the cyan, green, yellow, and orange regions of the spectrum has
had a significant impact on multicolor cellular imaging
experiments, greatly expanding the range of such experiments
that can be undertaken with laser scanning cytometry technology.
With the introduction of this new functionality, our
customers can capitalize immediately on the availability of
these remarkable fluorescent proteins. We are also pleased with
an additional benefit of the new hardware – our instruments are
renowned for their robust and reliable performance, and the new
hardware design provides even greater operational stability.”
“The instrument
configuration with violet, blue, yellow, and red lasers is an
instant winner with researchers,” stated Dr. Elena Holden,
CompuCyte’s President and CEO.
“It allows them to take full advantage of the most
efficient members in the new ’fruit‘ series of fluorescent
proteins, while at the same time providing full coverage of the
chromatic dye absorption spectrum.
The four-laser instruments offer researchers unmatched
flexibility in the choice and combination of dyes, both
fluorescent and chromatic.
As a testament to the value of these new products, the
first LSC upgrades were pre-ordered in March, in anticipation of
their scheduled release in the fall of 2009. New instrument
shipments began in November,” she said.
"The
four-laser iCys is an important tool in our cancer research,"
stated Dr. Alexei Protopopov, Director of the Molecular
Cytogenetics Laboratory and Senior Scientist at Dana-Farber
Cancer Institute in
Boston,
Massachusetts.
"The added laser gives us tremendous flexibility in dye
selection and allows more stains to be used simultaneously,
providing unprecedented multiplexing capabilities in our
analyses of cells and tissues.
We can now look at a number of indicators of tumor cell
behavior simultaneously--telomere erosion, centromere dynamics,
and expression of specific proteins, for example.
CompuCyte's new four-laser instrument represents a major
step forward in high-content cellular and tissue analysis,
greatly facilitating our understanding of cancer."
CompuCyte
Corporation, a private company headquartered in Westwood,
Massachusetts, is a pioneer in the field
of quantitative imaging cytometry (QIC). The company’s line of
laser scanning cytometry instrumentation is applied to automated
cellular and tissue analysis in life science research, drug
safety, toxicology studies and clinical trials. Committed to
educational programs and promotion of the science and practice
of LSC technology, CompuCyte actively maintains the
International
QIC Centers
of Excellence program (www.imagingcytometrycenter.com)
and the annual International QIC Symposium.
More information about CompuCyte Corporation and its
technology may be found at
www.compucyte.com.
|
